Tevogen Bio™ Appoints Prominent Industry Leader Susan Podlogar to the Company’s Corporate Advisory Board

• Tevogen’s Corporate Advisory Board represents distinguished industry leaders, policy experts, and patient advocates to provide guidance as the company continues to expand its next generation Precision T cell Platform Technology

METUCHEN, N.J.–(BUSINESS WIRE)–#CD8—Tevogen Bio, a clinical stage biotechnology company specializing in developing cell and gene therapies in oncology, neurology, and virology, today announced that its Board of Directors has appointed Susan Podlogar to its Corporate Advisory Board. Podlogar is currently MetLife’s Chief Human Resources Officer, an Executive Vice President and member of MetLife’s Executive Leadership Team.

The Corporate Advisory Board provides guidance to Tevogen leadership as the company continues to expand its next generation precision T cell platform, overcoming the barriers of existing T cell-based immunotherapies and allowing one of nature’s most powerful weapons against diseases to be harnessed to its full potential for clinical applications.

“I am excited to join this highly experienced team who embraces a think tank mentality, which I believe is key to Tevogen’s impressive progress. They are truly developing the next frontier of medicine with T cell technology,” said Podlogar. “I believe Tevogen’s culture of free-flowing ideas, where every idea is explored, is foundational to their successful business model and is due to the inventive spirit of its CEO, Dr. Ryan Saadi. Beyond cultivating operational efficiency and scientific breakthroughs in the cell and gene therapy space, Tevogen’s corporate philosophy of cultivating human potential will beautifully serve all stakeholders, most importantly patients,” Podlogar added.

“Susan Podlogar is a brilliant strategist, and an innovative industry leader with decades of experience in the biopharma sector and we are privileged to have her joining our Corporate Advisory Board,” said Tevogen CEO Ryan Saadi, M.D., M.P.H. “Susan brings with her extensive experience in working with Board of Directors, CEOs, senior leadership teams, and institutional investors. Her diverse experience in human resources roles in a multitude of business lifecycles and sectors, as well as her unparalleled track record of success in leading complex organizational transformations, will be a tremendous asset in guiding Tevogen as it continues to carve out a new frontier of business and medicine,” Saadi added.

Podlogar joined MetLife in July 2017 and oversees the company’s global Human Resources strategies and practices with the goal of attracting, developing, and retaining a purpose-driven, and energized workforce that creates sustainable value for MetLife’s customers and shareholders every day. Among her multiple initiatives at MetLife, Podlogar championed the signing of the Catalyst CEO Champions for Change Pledge—a commitment to advance diversity, inclusion, and gender equality in the workplace, as well as a partnership with the UN Women Global Innovation Coalition. Previously, during her 16 years with Johnson & Johnson, Podlogar held a series of sector and corporate leadership roles in HR in which she introduced Human Resources strategies and practices that helped strengthen the company’s business model, accelerate the pace of innovation, and evolve its talent capabilities and culture.

Podlogar earned an MBA from the University of South Florida, graduating summa cum laude, with concentrations in Finance and Management, and a Bachelor of Science degree from the University of Wisconsin-Parkside, also summa cum laude, with a double major in Labor and Industrial Relations and Business Administration.

About Tevogen’s Next Generation Precision T Cell Platform

Tevogen’s next generation precision T cell platform is designed to provide increased specificity to eliminate malignant and viral infected cells, while allowing healthy cells to remain intact. Multiple targets are selected in advance to overcome mutational capacity of cancer cells and viruses.

Tevogen believes its technology has the potential to overcome the primary barriers to the broad application of personalized T cell therapies: potency, purity, production-at-scale, and patient-pairing, without the limitations of current approaches. Tevogen’s goal is to open the vast and unprecedented potential of developing personalized immunotherapies for large patient populations impacted by common cancers and viral infections.

The company’s lead product, TVGN-489, is currently in clinical trials for high-risk COVID-19 patients at Jefferson University Hospitals in Philadelphia. TVGN-489 is a highly purified, SARS-CoV-2-specific cytotoxic CD8+ T lymphocyte (CTL) product, which is designed to detect targets spread across the entire viral genome.

Tevogen recently announced it has completed dosing of the second cohort of patients in the proof of concept clinical trial of TVGN-489, marking the midway point of the trial’s planned four dosing levels. Trial details and recruitment information are available at Clinical Trials – Tevogen.

About Tevogen Bio

Tevogen Bio is driven by a team of distinguished scientists and highly experienced biopharmaceutical leaders who have successfully developed and commercialized multiple franchises. Tevogen’s leadership believes that accessible personalized immunotherapies are the next frontier of medicine, and that disruptive business models are required to sustain medical innovation in the post-pandemic world.

Forward Looking Statements

This press release contains certain forward-looking statements relating to Tevogen Bio™ Inc.’s (the “Company”) development and patient access of its innovations in infectious diseases and oncology. These statements are based on management’s current expectations and beliefs as of the date of this release and are subject to a number of factors which involve known and unknown risks, delays, uncertainties, and other factors not under the company’s control which may cause actual results, performance or achievements of the company to be materially different from the results, performance or other expectations implied by these forward-looking statements. In any forward-looking statement in which the Company expresses an expectation or belief as to future results, such expectations or beliefs are expressed in good faith and are believed to have a reasonable basis, but there can be no assurance that the statement or expectation or belief will be achieved. These factors include results of current or pending clinical trials, risks associated with intellectual property protection, financial projections, sales, pricing and actions by the FDA/EMA. The Company undertakes no obligation to update the forward-looking statements or any of the information in this release, or provide additional information, and expressly disclaims any and all liability and make no representations or warranties in connection herewith or with respect to any omissions herefrom.

Contacts

Katelyn Joyce

Corporate Communications Lead

[email protected]